Effectiveness of vedolizumab dose escalation in inflammatory bowel disease in a large-scale, Canadian real-world cohort
For patients who experienced a suboptimal or loss of clinical response to vedolizumab, this study supports the real-world effectiveness of intravenous vedolizumab dose escalation in improving clinical response and clinical remission rates among patients with ulcerative colitis or Crohn's disease.
Authors
- Marie‐Julie Allard (ORCID: https://orcid.org/0000-0002-0742-0839)
- Ryan Ward (ORCID: https://orcid.org/0000-0002-4747-4305)
- Brian Bressler (ORCID: https://orcid.org/0000-0003-4740-8209)
- Jessica Weiss (ORCID: https://orcid.org/0000-0002-8679-9524)
- A. Hillary Steinhart (ORCID: https://orcid.org/0000-0001-7794-6150)
- Jean‐Frédéric LeBlanc (ORCID: https://orcid.org/0000-0002-8477-6337)
- Christopher Pettengell
- A. Wadhwa
- Edmond-Jean Bernard
Institutions
- University of British Columbia (CA)
- Pediatric Oncology Group (CA)
- University of Toronto (CA)
- Hôpital du Sacré-Cœur de Montréal (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Takeda (Canada) (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Journal of the Canadian Association of Gastroenterology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1093/jcag/gwaf033
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00